Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
December 15 2020 - 4:05PM
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced the appointment of Dr. Ana K.
Stankovic, MD, PhD, MSPH, to the company’s Board of Directors. Dr.
Stankovic is a seasoned leader with more than 30 years of research
and development experience in academic, government, in vitro
diagnostic and device industry settings.
Dr. Stankovic is currently managing partner at Koliada
Consulting, LLC, a firm focused on biotech, medical devices and in
vitro diagnostics. Previously, she was Senior Vice President, World
Wide Regional Medical Affairs and Global Health, for Becton,
Dickinson and Company (BD). Dr. Stankovic served in senior roles at
BD for more than a decade, leading medical affairs and clinical
operations for various BD business units.
Prior to her career at BD, she was Associate Clinical Professor,
Department of Pathology, Microbiology and Immunology, at Vanderbilt
University School of Medicine. She also served for two years as a
Guest Lecturer in the Department of Pathology at Harvard Medical
School. Dr. Stankovic is a former Chief Resident in the Department
of Pathology at the University of Alabama at Birmingham. She is a
boardcertified clinical pathologist with subspecialty training in
blood bank/transfusion medicine and hematopathology.
“I am honored to join the Fluidigm team at this
exciting time when the company’s leadership in infectious disease
testing and immune profiling has enabled it to play a major role in
addressing the COVID-19 pandemic,” said Dr. Stankovic. “Fluidigm is
positioned to make meaningful contributions to life science
research for the long term, and I am delighted for the opportunity
to be a part of that journey.”
Dr. Stankovic possesses significant public health experience.
She is a former official of the Centers for Disease Control and
Prevention, having served as Medical Officer, Public Health
Practice Program Office, Division of Laboratory Systems. Her career
also includes medical oversight and compliance posts at Quest
Diagnostics, Immucor, Inc., and the American Red Cross.
“Dr. Stankovic’s medical and public health expertise, coupled
with remarkably broad experience across clinical and scientific
institutions, makes her ideally suited to help us chart Fluidigm’s
course in 2021 and beyond,” said Chris Linthwaite, President
and CEO. “Her counsel will be particularly valuable as we execute
further our diagnostics roadmap, expand the role of our technology
in cuttingedge immunology research and clinical trials, and engage
more directly with government and public health agencies.
“Dr. Stankovic is a critical and welcome addition to our board
at this historic time for Fluidigm.”
Dr. Stankovic earned her MD at The University of Belgrade, where
she also obtained a PhD in Immunology. She holds a Master of
Science in Public Health, Health Policy and Outcomes Research from
the University of Alabama at Birmingham.
About Fluidigm Fluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or
registered trademarks of Fluidigm Corporation in the United States
and/or other countries. All other trademarks are the sole property
of their respective owners.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate Communications650
243 6621
mark.spearman@fluidigm.com
Investors:Agnes LeeVice President, Investor Relations650 416
7423
agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024